• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

    8/4/22 8:00:00 AM ET
    $GLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLMD alert in real time by email

    TEL AVIV, Israel, Aug. 4, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, fibrosis and other fibrotic indications, provides today a business update and reports financial results for the three and six months ended June 30, 2022.

    Recent Developments

    • Discontinuing the Open Label Part of the ARMOR study having reached its objectives while refocusing research and development on advancing Aramchol for new anti-fibrotic indications.
    • Implementing a cost reduction plan that includes reduction in headcount and full-time positions and discontinuing any non-essential research and development activities.
    • Evaluating the continuation of development of Aramchol and Amilo-5MER and unable to estimate if and when the registrational part of the ARMOR study will be initiated.
    • Continuing to explore strategic alternatives and structuring to best optimize resources to enhance shareholder value and achieve goals.
    Galmed Pharmaceuticals Logo

    Financial Summary – Second Quarter 2022 vs. Second Quarter 2021:

    • Cash and cash equivalents, restricted cash and marketable debt securities totaled $22.5 million as of June 30, 2022, compared to $34.9 million at December 31, 2021.
    • Net loss amounted to $3.7 million, or $0.15 per share, for the three months ended June 30, 2022, compared to a net loss of $8.4 million, or $0.33 per share, for the three months ended June 30, 2021.
    • Research and development expenses amounted to approximately $2.6 million for the three months ended June 30, 2022, compared to approximately $7.0 million for the three months ended June 30, 2021. The decrease resulted primarily from a decrease in clinical trial expenses in connection with the discontinuation of the Open Label Part of the ARMOR study.
    • General and administrative expenses amounted to approximately $1.1 million for the three months ended June 30, 2022, compared to approximately $1.4 million for the three months ended June 30, 2021. The decrease in general and administrative expenses for the three months ended June 30, 2022 resulted primarily from a decrease in professional services expenses.

    About Galmed Pharmaceuticals Ltd.

    Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases.

    Forward-Looking Statements:

    This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Galmed's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Galmed intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause Galmed's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the timing and cost of Galmed's pivotal Phase 3 ARMOR trial, or the ARMOR Study or any other pre-clinical or clinical trials; completion and receiving favorable results of the ARMOR Study for Aramchol or any other pre-clinical or clinical trial; the impact of COVID-19; regulatory action with respect to Aramchol or any other product candidate by the FDA or the EMA; the commercial launch and future sales of Aramchol or any other future products or product candidates; Galmed's ability to comply with all applicable post-market regulatory requirements for Aramchol or any other product candidate in the countries in which it seeks to market the product; Galmed's ability to achieve favorable pricing for Aramchol or any other product candidate; Galmed's expectations regarding the commercial market for NASH patients or any other indication; third-party payor reimbursement for Aramchol or any other product candidate; Galmed's estimates regarding anticipated capital requirements and Galmed's needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; the development and approval of the use of Aramchol or any other product candidate for additional indications or in combination therapy; Galmed's expectations regarding licensing, acquisitions and strategic operations; Galmed's ability to maintain the listing of its common stock on The Nasdaq Capital Market; and the outcome of any evaluation of Galmed's strategic alternatives. More detailed information about the risks and uncertainties affecting Galmed is contained under the heading "Risk Factors" included in Galmed's most recent Annual Report on Form 20-F filed with the SEC on May 2, 2022, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Logo - https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg

     

     

    GALMED PHARMACEUTICALS LTD.

    Consolidated Balance Sheets

    U.S. Dollars in thousands, except share data and per share data







    As of





    As of







    June 30,





    December 31,







    2022





    2021



    Assets

















    Current assets

















    Cash and cash equivalents



    $

    1,980







    2,884



    Restricted Cash





    114







    114



    Marketable debt securities





    20,422







    31,931



    Other receivable





    614







    1,125



    Total current assets





    23,130







    36,054





















    Right of use assets





    315







    406



    Property and equipment, net





    130







    145



    Total non-current assets





    445







    551





















    Total assets



    $

    23,575





    $

    36,605





















    Liabilities and stockholders' equity



































    Current liabilities

















    Trade payables



    $

    2,089





    $

    4,871



    Other accounts payables





    640







    1,008



    Total current liabilities





    2,729







    5,879





















    Non-current liabilities

















    Operating lease liabilities, net of current portion



    $

    134





    $

    229



    Total non-current liabilities





    134







    229





















    Ordinary shares par value NIS 0.01 per share; Authorized 300,000,000;

    Issued and outstanding:

















    25,088,414 shares as of June 30, 2022 and December 31, 2021





    70







    70



    Additional paid-in capital





    199,675







    198,772



    Accumulated other comprehensive loss





    (982)







    (171)



    Accumulated deficit





    (178,051)







    (168,174)



    Total stockholders' equity





    20,712







    30,497





















    Total liabilities and stockholders' equity



    $

    23,575





    $

    36,605



     

    The accompanying notes are an integral part of the interim consolidated financial statements.

     

     

    GALMED PHARMACEUTICALS LTD.

    Consolidated Statements of Operations (Unaudited)

    U.S. Dollars in thousands, except share data and per share data







    Three months ended





    Six months ended







    June 30,





    June 30,







    2022





    2021





    2022





    2021



    Research and development expenses





    2,580







    7,036







    7,376







    14,416





































    General and administrative expenses





    1,150







    1,376







    2,446







    3,128





































    Total operating expenses





    3,730







    8,412







    9,822







    17,544





































    Financial expense (income), net





    4







    (16)







    55







    (243)





































    Net loss



    $

    3,374





    $

    8,396





    $

    9,877





    $

    17,301





































    Basic and diluted net loss per share



    $

    0.15





    $

    0.33





    $

    0.39





    $

    0.72





































    Weighted-average number of shares outstanding used in

































    computing basic and diluted net loss per share





    25,088,414







    25,083,914







    25,088,414







    24,099,132



     

     

    GALMED PHARMACEUTICALS LTD.

    Consolidated Statements of Cash Flows (Unaudited)

    U.S. Dollars in thousands







    Six months ended







    June 30,







    2022





    2021



    Cash flow from operating activities



































    Net loss



    $

    (9,877)





    $

    (17,301)





















    Adjustments required to reconcile net loss to net cash used in operating activities

















    Depreciation and amortization





    18







    21



    Stock-based compensation expense





    903







    943



    Amortization of premium on marketable debt securities





    35







    126



    Interest income from short-term deposits





    -







    (7)



    Loss (gain) from realization of marketable debt securities





    201







    (19)



    Finance expenses





    (42)







    -



    Changes in operating assets and liabilities:

















    Decrease in other accounts receivable





    511







    325



    Decrease in trade payables





    (2,782)







    (1,417)



    Increase (decrease) in other accounts payable





    (330)







    412)



    Net cash used in operating activities





    (11,363)







    (16,917)





















    Cash flow from investing activities

















    Purchase of property and equipment





    (3)







    (8)



    Investmentin available for sale securities













    (7,831)



    Sale (investment) in short term deposits, net





    -







    2,005



    Consideration from sale of available for sale securities





    10,462







    6,359



    Net cash provided by (used in) investing activities





    10,459







    525





















    Cash flow from financing activities

















    Proceeds from exercise of options (*)





    -







    (*)



    Issuance of Ordinary shares, net of issuance cost





    -







    17,368



    Net cash provided in financing activities





    -







    17,368





















    Increase (decrease) in cash and cash equivalents and restricted cash





    (904)







    976



    Cash and cash equivalents and restricted cash at the beginning of the period





    2,998







    7,060



    Cash and cash equivalents and restricted cash at the end of the period



    $

    2,094





    $

    8,036



    Supplemental disclosure of cash flow information:



































    Cash received from interest



    $

    138





    $

    347



    Non-cash transactions:

















    Right-of-use assets obtained in exchange for new operating lease liabilities, net



    $

    -





    $

    530



    (*) Represents amount less than $1.

     

     

    Cision View original content:https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-provides-business-update-and-reports-second-quarter-2022-financial-results-301599992.html

    SOURCE Galmed Pharmaceuticals Ltd.

    Get the next $GLMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GLMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GLMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

      Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways.Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets.Strategic collaboration with Proteas Health positions Galmed at the forefront of AI-driven biomarker-guided therapeutics.TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver, cardiometabolic diseases and GI

      5/27/25 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments. Key Recent Developments Announced First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsSigned Term Sheet for the Development of Novel Semaglutide Sublingual FormulationRaised $6.5 million since the beginning of 2025. Company's current cash balance is $20.1 millionFinancial Summary – First Quarter 2025 vs. First Quarte

      5/22/25 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models

      Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC)Aramchol treatment leads to significant inhibition (2-fold, p<0.05) of TGFβ-induced hepatic fibrosis pathways while upregulating peroxisome proliferator activated receptor (PPAR) signalingAramchol's effect in the prevention and treatment of biliary and hepatic fibrosis, provides the rationale for assessing Aramchol in further clinical studies in patients with fibrosis driven liver cancersTEL AVIV, Israel, May 13, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardi

      5/13/25 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLMD
    SEC Filings

    See more
    • SEC Form 6-K filed by Galmed Pharmaceuticals Ltd.

      6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

      5/27/25 8:15:28 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galmed Pharmaceuticals Ltd.

      6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

      5/22/25 8:00:17 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galmed Pharmaceuticals Ltd.

      6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

      5/13/25 8:24:24 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity reiterated coverage on Galmed Pharmaceuticals with a new price target

      Canaccord Genuity reiterated coverage of Galmed Pharmaceuticals with a rating of Buy and set a new price target of $21.00 from $20.00 previously

      5/17/21 10:09:42 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Galmed Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Galmed Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $29.00 previously

      3/19/21 6:22:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Galmed Pharmaceuticals Ltd.

      SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

      11/14/24 12:24:34 PM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Galmed Pharmaceuticals Ltd.

      SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

      9/20/24 2:18:08 PM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Galmed Pharmaceuticals Ltd.

      SC 13G - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

      9/20/24 2:17:11 PM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLMD
    Financials

    Live finance-specific insights

    See more
    • Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments. Key Recent Developments Announced First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsSigned Term Sheet for the Development of Novel Semaglutide Sublingual FormulationRaised $6.5 million since the beginning of 2025. Company's current cash balance is $20.1 millionFinancial Summary – First Quarter 2025 vs. First Quarte

      5/22/25 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

      TEL AVIV, Israel, June 1, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments Recent Developments Initiated a new clinical program to evaluate its lead compound, Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC), a rare disease for which there is no approved treatment;Phase 2 proof of concept PSC study to be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University;Formed a str

      6/1/23 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

      TEL AVIV, Israel, Aug. 4, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, fibrosis and other fibrotic indications, provides today a business update and reports financial results for the three and six months ended June 30, 2022. Recent Developments Discontinuing the Open Label Part of the ARMOR study having reached its objectives while refocusing research and development on advancing Aramchol for new anti-fibrotic indications.Implementing a cost reduction plan that includes reduction in headc

      8/4/22 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care